Overall survival with cisplatin–gemcitabine and bevacizumab or placebo as first-line therapy for nonsquamous non-small-cell lung cancer: results from a randomised phase III trial (AVAiL)

Background: Bevacizumab, the anti-vascular endothelial growth factor agent, provides clinical benefit when combined with platinum-based chemotherapy in first-line advanced non-small-cell lung cancer. We report the final overall survival (OS) analysis from the phase III AVAiL trial. Patients and meth...

Descripción completa

Detalles Bibliográficos
Autores principales: Reck, M., von Pawel, J., Zatloukal, P., Ramlau, R., Gorbounova, V., Hirsh, V., Leighl, N., Mezger, J., Archer, V., Moore, N., Manegold, C.
Formato: Texto
Lenguaje:English
Publicado: Oxford University Press 2010
Materias:
Original Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2924992/
https://www.ncbi.nlm.nih.gov/pubmed/20150572
http://dx.doi.org/10.1093/annonc/mdq020

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2924992/
https://www.ncbi.nlm.nih.gov/pubmed/20150572
http://dx.doi.org/10.1093/annonc/mdq020

Ejemplares similares